Pulse Biosciences, Inc. (PLSE)
Pulse Biosciences, Inc. operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Miami, FL, US. The stock last traded at $43.21, down 2.68% on the session, giving a market capitalisation of $2.99B. On trailing twelve-month figures it carries a trailing P/E of -36.93, a net margin of -6755.8%. Its beta of 1.58 implies it has historically moved more than the broad market.
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Pulse Biosciences, Inc. is most often compared with the following Healthcare names: